|
Mr. Luci joined MacroChem in December 2007. Prior to joining MacroChem Mr. Luci served as Executive Vice President General Counsel & Corporate Secretary of Bioenvision where he established the company’s offices in New York raised over $100 million in capital and advanced Bioenvision stock listing from OTCBB to AMEX and then to NASDAQ. He was also responsible for garnering analyst interest for a number of investment firms and served as Chief Financial Officer for five years. While at Bioenvision he in-licensed the company’s development-stage lead cancer drug for Japan and Southeast Asia and initiated drug development activities in Japan. He later successfully guided Bioenvision into a merger agreement and closing of a related tender offer with its U.S. co-development partner Genzyme in a transaction valued at approximately $345 million. Prior to joining Bioenvision Mr. Luci practiced securities law and mergers and acquisitions at Paul Hastings Janofsky and Walker LLP New York from 1994 to 2002. Prior to Paul Hastings he was Senior Auditor Ernst and Young New York from 1988 to 1991 focused on internal audit and controls within the Mergers and Acquisitions Practice Group. He is also a member of the Board of Directors and Chairman of the Audit Committee and Compensation Committee of Access Pharmaceuticals Inc.
Mr. Luci received his JD cum laude from Albany Law School of Union University (1994) and his Bachelor of Science in Business Administration with a concentration in accounting from Bucknell University (1988). He is a member of the New York State Bar Association and a Certified Public Accountant (Pennsylvania). | 